Astrazeneca Share News (AZN)

AstraZeneca 'disappointed' with FDA panel vote on prostate drug

(Sharecast News) - AstraZeneca said it was disappointed with a decision by a panel of US Food and Drug Administration advisers to restrict use of its treatment for a type of prostate cancer.

AstraZeneca "disappointed" with US ODAC's guidance on Lynparza

(Alliance News) - AstraZeneca PLC on Friday said the US Food & Drug Administration's Oncologic Drugs Advisory Committee has recognised a favourable benefit risk profile for its Lynparza, plus abiraterone and prednisone or prednisolone, for the treatment of adult patients with BRCA-mutated metastatic castration-resistant prostate cancer.

US FDA panel backs restricted use of AstraZeneca's prostate cancer drug

April 28 (Reuters) - A panel of U.S. Food and Drug Administration advisers on Friday voted for the restricted use of British drugmaker AztraZeneca Plc's experimental treatment, jointly developed with Merck & Co, for a type of prostate cancer.

US FDA panel backs AstraZeneca's prostate cancer drug

April 28 (Reuters) - A panel of U.S. Food and Drug Administration advisers on Friday voted for the expanded use of British drugmaker AztraZeneca Plc's experimental treatment, jointly developed with Merck & Co, for a type of prostate cancer.

Drugmakers scout for deals, ramp up research spending

April 27 (Reuters) - Drugmakers including Merck & Co , AstraZeneca Plc and AbbVie Inc said on Thursday they are open to acquisitions and reported a ramp up in research and development spending as the industry's larger players look for new sources of future revenue.

FTSE 100 closes lower for fourth day; Barclays shines

Unilever climbs on upbeat Q1 sales

*

Drugmakers scout for deals, ramp up research spending

April 27 (Reuters) - Drugmakers including Merck & Co , AstraZeneca Plc and AbbVie Inc said on Thursday they are open to acquisitions and reported a ramp up in research and development spending as the industry's larger players look for new sources of future revenue.

AstraZeneca increases bets on China as COVID vaccine sales fade

AstraZeneca already biggest drugmaker in China

*

AstraZeneca beats estimates on strong emerging market sales as COVID wanes

LONDON, April 27 (Reuters) - AstraZeneca on Thursday beat expectations for first-quarter profit and revenue, as buoyant sales of cancer treatment Imfinzi and strong demand for its roster of drugs in emerging markets helped to offset dwindling COVID product sales.

TOP NEWS: AstraZeneca profit jumps despite Covid-19 sales decline

(Alliance News) - AstraZeneca PLC on Thursday said revenue decreased in the first quarter of the year as Covid-19 related sales dropped, but pretax profit surged.

LONDON MARKET OPEN: Stocks lower amid worries for health of US economy

(Alliance News) - Stock prices in London opened lower on Thursday, with the FTSE 100 failing to get a boost by positive first-quarter results from major constituents including Barclays and AstraZeneca.

LONDON BRIEFING: AstraZeneca revenue dips as Covid medicines decline

(Alliance News) - Stocks in London were set to open lower on Thursday, as investors concern continued to mount about the health of the US banking sector after another largely lower finish in New York.

AstraZeneca beats Q1 estimates

(Sharecast News) - AstraZeneca posted better-than-expected first quarter results and reiterated its full-year guidance.

European shares fall as healthcare stocks hit by drug reforms

Healthcare index marks biggest decline in 15 months

*

LONDON MARKET CLOSE: Tech shines but tepid trade elsewhere

(Alliance News) - European equities closed lower on Wednesday, with lingering banking sector worries hurting sentiment, while tech stocks outperformed wider markets in New York after well-received earnings overnight.